Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
Abstract Background Aldosterone is categorized as a mineralocorticoid hormone produced in the zona glomerulosa of the adrenal cortex. Aldosterone has considerable action in sodium and water retention along with cardiac remodeling, promoting fibrosis and these detrimental effects have been counteract...
Saved in:
| Main Authors: | Akshyaya Pradhan, Umesh Chandra Tripathi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-12-01
|
| Series: | The Egyptian Heart Journal |
| Online Access: | https://doi.org/10.1186/s43044-024-00586-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01) -
The use of mineralocorticoid antagonists in chronic heart failure
by: Andrea Szegedi, et al.
Published: (2025-07-01) -
Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD
by: Fang Li, et al.
Published: (2025-12-01) -
Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor
by: Jeovanna Lowe, et al.
Published: (2025-12-01) -
Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease
by: Mariana Morais David Pliças, et al.
Published: (2025-03-01)